香港醫思醫療(2138.HK)高開7.81% 溢價約1.56%向鄭志剛及基金募資 淨籌2.3億港元
格隆匯4月19日丨香港醫思醫療集團(2138.HK)跳空高開7.81%,報8.28港元,最新總市值88億港元。公司今日早間公佈,於4月16日交易時段後,公司以每股7.8港元向鄭志剛及私人投資基金形式營運的Aspex Master Fund配售29,636,000股新股,新股佔公司經擴大已發行股本的約2.69%。配售價較上週五收市價每股股份7.68港元溢價約1.56%。配售事項的估計所得款項總額及所得款項淨額將分別約為2.312億港元及2.31億港元。公司擬將配售事項所得款項淨額用於擴大集團於中國香港及中國大灣區的診所網絡、併購及集團的一般企業用途。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.